Absorbable scaffolds regenerate lost breast tissue
As of 1 July, 30 Australian women have now undergone restorative breast surgery using an absorbable scaffold technology specifically designed to regenerate lost breast tissue. This number is across two trials: a first-in-human safety study involving 19 patients between 2021 and 2023, and a pivotal clinical trial launched in January 2026 in Australia.
The proprietary scaffolds — by clinical-stage regenerative medicine company BellaSeno GmbH — are inserted into the breast and seeded with the patient’s own fat, acting as a protective framework for tissue growth, gradually regenerating breast volume and shape over one to two years. According to BellaSeno, 11 patients have undergone scaffold surgery in the current trial as of 1 July, with dozens more enrolled.
Surgeons and Principal Investigators Professor Owen Ung and Professor Anand Deva, both based in Australia, led BellaSeno’s clinical program, with Deva presenting the two-year outcomes of the first-in-human safety study in June 2026, at The Aesthetic MEET 2026 in Boston.
“The results showed no scaffold-related complications such as capsular contracture, infection, necrosis, calcification, oil cysts or scaffold removals in the study cohort,” BellaSeno said. “They also demonstrated high patient-reported satisfaction, with 83% mean breast volume retention, and soft, natural-feeling tissue outcomes.”
Deva said: “There are now 30 women walking around the world who have had breast scaffold surgery across both trials. By the end of August, we expect that number will more than double as we have many more patients scheduled for surgery.
“By the time we conclude this trial, we will have generated a robust scientific evidence base focused on efficacy, safety and longer-term patient outcomes,” Deva added. “It is without a doubt the most significant advancement we have seen in the field of breast surgery for decades. We have now entered the era of medical regeneration.”
BellaSeno co-founder and CEO Dr Mohit P. Chhaya said the progress to date reflected years of collaboration between scientists, engineers, surgeons and patients and a common belief that future health care will increasingly involve technologies designed to unlock the body’s own regenerative capacity.
Chhaya also said: “we are now considering the pathway from clinical investigation toward future commercialisation and broader clinical access.
“Regenerative soft tissue surgery is no longer a futuristic idea. Dozens of patients have had these procedures, and many more are going to as part of human clinical studies, which are happening inside operating theatres now.”
More information on the active pivotal clinical trial is available at www.bellaseno.com/breast-scaffold.
Proteomics International PromarkerD predictive test for diabetic kidney disease
The product is a clinically validated blood test that can predict the risk of developing chronic...
Phenosys Jet Ball rodent virtual reality system
The Jet Ball by Phenosys is a novel virtual reality experimental system based on an air...
Illumina Nextera Flex for Enrichment sequencing solution
The Illumina Nextera Flex for Enrichment is a targeted sequencing solution.
